Furthermore, the activity of SEMA6A/RhoA/YAP axis is induced by dual BRAF/MEK inhibition by dabrafenib+trametinib and, in an environmental-mimicking condition of melanoma cells and fibroblasts co-culture, is associated with reduced targeted therapy efficacy. This evidence concerns the gene MAP2K7 and melanoma.